Taysha IPO Presentation Deck

Deep pipeline of gene therapies targeting genetic epilepsies TSHA-103 GRT SLC6A1 IND-enabling studies TSHA-105 GRT SLC13A5 Preclinical TSHA-110 GRT KCNQ2 Preclinical . SLC6A1 encodes for GAT1 transporter, responsible for the reuptake of GABA Lack of GAT1 function results in impaired brain development, attention deficit and seizures Estimated prevalence of 16,000 patients in the US and EU Bi-allelic loss of function in the SLC13A5 gene, resulting in diminished NaCT function Patients have impaired motor function, speech production, and seizures Estimated prevalence of over 220 patients in the US and EU Diminished KCNQ2 function results in seizures in the first week of life, accompanied by developmental delay involving one or more domains of motor, social, language, or cognition Some children may have autistic features Estimated prevalence of 17,000 patients in the US and EU T 40

View entire presentation